City Therapeutics Raised $100 Million for RNAi Pipeline
The Cambridge-based firm secured fresh capital to move its gene-silencing therapies into initial human trials.
Live Poll
Do you support biotechnology startups relying on major pharmaceutical companies to fund their drug development?
